LAS VEGAS, Sept. 3, 2020
LAS VEGAS, Sept. 3, 2020 /PRNewswire/ -- DelveInsight has launched a new report 'Acute Respiratory Distress Syndrome (ARDS) Market Insight, Epidemiology, and Market Forecast -2030' in its pharma market research report portfolio.
Request for Sample Pages of the Report: https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-market
Acute respiratory distress syndrome is a rapidly progressive condition resulting in an excess buildup of fluid in the lungs. The condition leads to insufficient supply oxygen in the body leading to breathing difficulties, dysfunction of organs such as kidney, brain. ARDS, if not diagnosed and treated timely, can be life-threatening.
Acute respiratory distress syndrome incidence varies depending on demographic and environmental risks.
The Acute respiratory distress syndrome market report proffers in-depth epidemiological segmentation analysis for the study period 2017-30:
Acute Respiratory Distress Syndrome Market
Acute respiratory distress syndrome market offers supportive treatments including supplemental oxygen, prone positioning, paralytics, fluid management, and positive end-expiratory pressure (PEEP). These treatment approaches are bundled with medications such as antibiotics to help patients fight lung infection. Also, supportive treatment, such as intravenous fluid or food, are given to patients.
Β2 agonists, Statins, Neuromuscular blocking agents (NMBAs) are some of the other treatment approaches used to address ARDS. However, their use remains controversial. Pancuronium and Vecuronium are the most commonly used NMBAs for the management of ARDS.
Despite the presence of several treatment options, the mortality rate in ARDS is very high. The treatment options available in the Acute respiratory distress syndrome market are generally supportive and restricted to mechanical ventilation. Poor disease understanding, as well as poor diagnosis, are other roadblocks present in the ARDS market size growth. The market has also experienced hidden snags in the form of failure of the trials and global pandemic COVID-19 that have slowed the market size growth.
However, the launch of emerging therapies shall transform the ARDS market landscape positively. Premium-price agents such as stem cell therapies and other ARDS pipeline therapies with a better clinical profile are expected to dominate the ARDS market. Several pharma companies are running trials and evaluating various novel molecules to strengthen the pipeline.
With the ARD pipeline therapies such as Traumakine (Faron Pharmaceuticals) Bio11006 (BioMarck Pharmaceuticals), MultiStem (Athersys), Solnatide (Apeptico Forschung und Entwicklung GmbH), PB1046 (PhaseBio Pharmaceuticals), and others shall further create a positive impact on the market. Some of the pipeline therapies to be launched in the forecast period 2020-30 are:
ARDS Pipeline Therapies
As per DelveInsight's analysis, the Acute respiratory distress syndrome market is anticipated to grow in the forecast period 2020-30 owing to the launch of pipeline therapies, increasing cases of the disease, better awareness among people and prominent research ongoing in the field. At present, there is no approved therapy available in the ARDS treatment market; hence it offers great opportunities to pharma and biotech players worldwide to grab the market chunk. It is expected that the ARDS market size of the currently available supportive therapies shall experience steady growth throughout the study period [2017–2030]. The increasing disease awareness, ARDS incidence, and heightened R&D in the domain are other driving factors expediting the ARDS market growth.
Identify Key Trends of ARDS Market Report: https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-ards-market
Scope of the Report
Reason to purchase
Table of Contents
Executive Summary of Acute Respiratory Distress Syndrome (ARDS)
Competitive Intelligence Analysis for Acute Respiratory Distress Syndrome
Acute Respiratory Distress Syndrome Market Overview at a Glance
Acute Respiratory Distress Syndrome Disease Background and Overview
Acute Respiratory Distress Syndrome Patient Journey
Acute Respiratory Distress Syndrome Epidemiology and Patient Population
Acute Respiratory Distress Syndrome Treatment Algorithm, Current Treatment, and Medical Practices
Acute Respiratory Distress Syndrome Unmet Needs
Key Endpoints of Acute Respiratory Distress Syndrome Treatment
Acute Respiratory Distress Syndrome Marketed Products
Acute Respiratory Distress Syndrome Emerging Therapies
Acute Respiratory Distress Syndrome 7 Major Market Analysis
7MM: Acute Respiratory Distress Syndrome Market Outlook
Access and Reimbursement Overview of Acute Respiratory Distress Syndrome
Acute Respiratory Distress Syndrome Market Drivers
Acute Respiratory Distress Syndrome Market Barriers
Request a WebEx Walkthrough of the Report: https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-ards-market
DelveInsight's "Respiratory syncytial virus (RSV) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Respiratory syncytial virus (RSV), historical and forecasted epidemiology as well as the Respiratory syncytial virus (RSV) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The recently launched report by DelveInsight covers detailed analysis of 50+ companies working for the development of drugs and vaccines as well as diagnostics companies are working on developing test kits.
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.